ACB vs. CRON, THCX, GUD, CPH, FIRE, WEED, EPI, OGI, ICC, and RIV
Should you be buying Aurora Cannabis stock or one of its competitors? The main competitors of Aurora Cannabis include Cronos Group (CRON), Hydropothecary (THCX), Knight Therapeutics (GUD), Cipher Pharmaceuticals (CPH), Supreme Cannabis (FIRE), Canopy Growth (WEED), ESSA Pharma (EPI), Organigram (OGI), ICC Labs (ICC), and RIV Capital (RIV). These companies are all part of the "drug manufacturers - specialty & generic" industry.
Aurora Cannabis vs.
Cronos Group (TSE:CRON) and Aurora Cannabis (TSE:ACB) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, community ranking, earnings, dividends, analyst recommendations, valuation and media sentiment.
16.0% of Cronos Group shares are held by institutional investors. Comparatively, 13.4% of Aurora Cannabis shares are held by institutional investors. 46.4% of Cronos Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Aurora Cannabis has a net margin of -11.53% compared to Cronos Group's net margin of -56.43%. Cronos Group's return on equity of -5.29% beat Aurora Cannabis' return on equity.
Cronos Group presently has a consensus price target of C$3.54, indicating a potential upside of 25.98%. Aurora Cannabis has a consensus price target of C$7.11, indicating a potential downside of 22.61%. Given Cronos Group's higher possible upside, equities research analysts plainly believe Cronos Group is more favorable than Aurora Cannabis.
Aurora Cannabis received 462 more outperform votes than Cronos Group when rated by MarketBeat users. Likewise, 63.14% of users gave Aurora Cannabis an outperform vote while only 50.74% of users gave Cronos Group an outperform vote.
Cronos Group has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Comparatively, Aurora Cannabis has a beta of 2.71, suggesting that its share price is 171% more volatile than the S&P 500.
Aurora Cannabis has higher revenue and earnings than Cronos Group. Aurora Cannabis is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.
In the previous week, Aurora Cannabis had 16 more articles in the media than Cronos Group. MarketBeat recorded 17 mentions for Aurora Cannabis and 1 mentions for Cronos Group. Cronos Group's average media sentiment score of 0.59 beat Aurora Cannabis' score of 0.35 indicating that Cronos Group is being referred to more favorably in the media.
Summary
Aurora Cannabis beats Cronos Group on 10 of the 18 factors compared between the two stocks.
Get Aurora Cannabis News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Aurora Cannabis Competitors List
Related Companies and Tools
This page (TSE:ACB) was last updated on 2/12/2025 by MarketBeat.com Staff